Goldman Sachs
NDRM

Goldman Sachs’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Goldman Sachs’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-57,500
Closed -$1.53M – 7218
2017
Q1 		$1.53M Buy
57,500
+7,500
+15% +$186K ﹤0.01% 4015
2016
Q4 		$1.11M Buy
+50,000
New +$935K ﹤0.01% 4355

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Goldman Sachs's NDRM Position: Q4 2017 in Review

Goldman Sachs sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 369,029 shares — an estimated $14.4M sold.

Goldman Sachs first reported a position in NDRM in Q4 2014 and held it in 9 quarters. The position peaked at $14.4M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Goldman Sachs reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 369,029 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $14.4M.
  • Goldman Sachs first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 9 quarters.
  • Goldman Sachs's NeuroDerm Ltd. Ordinary Shares position peaked at $14.4M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.